OBJECTIVE: The reported frequency of aborted MRI-guided breast biopsies ranges from 8% to 17%, usually secondary to nonvisualization at attempted biopsy. Our study examines the frequency of MRI-guided breast biopsies aborted because of lesion nonvisualization and the subsequent risk of malignancy. MATERIALS AND METHODS: We identified 350 patients and 445 lesions scheduled for MRI-guided biopsy between January 1, 2007, and December 31, 2009. Medical records and imaging studies were reviewed to ascertain patient demographics, lesion and imaging characteristics, and subsequent pathology results. Chi-square statistics were calculated for patient level analyses. RESULTS: MRI-guided biopsies were aborted in 13% (56/445) of lesions and 15% (53/350; 95% CI, 11.6-19.3%) of patients because of nonvisualization of the biopsy target at the time of attempted biopsy. Of these 53 patients, 50 patients had follow-up data available. Malignancy was subsequently diagnosed in five of those 50 patients (10%; 95% CI, 3.3-21.8%), three with invasive ductal carcinomas and two with ductal carcinoma in situ. The mean time to malignant diagnosis from the date of aborted biopsy was 2.6 months (range, 1.1-6.9 months). CONCLUSION: Informed consent for MRI-guided breast biopsies should include discussion of biopsy cancellation because of nonvisualization of the target lesion. The low yet significant risk of malignancy in patients subsequent to an aborted MRI-guided breast biopsy warrants short-term follow-up MRI after a canceled biopsy.
OBJECTIVE: The reported frequency of aborted MRI-guided breast biopsies ranges from 8% to 17%, usually secondary to nonvisualization at attempted biopsy. Our study examines the frequency of MRI-guided breast biopsies aborted because of lesion nonvisualization and the subsequent risk of malignancy. MATERIALS AND METHODS: We identified 350 patients and 445 lesions scheduled for MRI-guided biopsy between January 1, 2007, and December 31, 2009. Medical records and imaging studies were reviewed to ascertain patient demographics, lesion and imaging characteristics, and subsequent pathology results. Chi-square statistics were calculated for patient level analyses. RESULTS: MRI-guided biopsies were aborted in 13% (56/445) of lesions and 15% (53/350; 95% CI, 11.6-19.3%) of patients because of nonvisualization of the biopsy target at the time of attempted biopsy. Of these 53 patients, 50 patients had follow-up data available. Malignancy was subsequently diagnosed in five of those 50 patients (10%; 95% CI, 3.3-21.8%), three with invasive ductal carcinomas and two with ductal carcinoma in situ. The mean time to malignant diagnosis from the date of aborted biopsy was 2.6 months (range, 1.1-6.9 months). CONCLUSION: Informed consent for MRI-guided breast biopsies should include discussion of biopsy cancellation because of nonvisualization of the target lesion. The low yet significant risk of malignancy in patients subsequent to an aborted MRI-guided breast biopsy warrants short-term follow-up MRI after a canceled biopsy.
Authors: C Perlet; A Heinig; X Prat; J Casselman; L Baath; H Sittek; C Stets; J Lamarque; I Anderson; P Schneider; P Taourel; M Reiser; S H Heywang-Köbrunner Journal: Eur Radiol Date: 2002-04-24 Impact factor: 5.315
Authors: L Hefler; J Casselman; B Amaya; A Heinig; T Alberich; H Koelbl; S H Heywang-Köbrunner Journal: Eur Radiol Date: 2002-10-03 Impact factor: 5.315
Authors: Laura Liberman; Nanette Bracero; Elizabeth Morris; Cynthia Thornton; D David Dershaw Journal: AJR Am J Roentgenol Date: 2005-07 Impact factor: 3.959
Authors: Jean-Paul Delille; Priscilla J Slanetz; Eren D Yeh; Daniel B Kopans; Leoncio Garrido Journal: Breast J Date: 2005 Jul-Aug Impact factor: 2.431
Authors: Linda R LaTrenta; Jennifer H Menell; Elizabeth A Morris; Andrea F Abramson; D David Dershaw; Laura Liberman Journal: Radiology Date: 2003-06 Impact factor: 11.105
Authors: Beatriz E Adrada; Mary S Guirguis; Tuan Hoang; David A Spak; Gaiane M Rauch; Tanya W Moseley Journal: Radiographics Date: 2022-02-04 Impact factor: 5.333